Pancreatic Cancer Research

Clinical trialPhase 3Completed

EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX

A Randomized Controlled, Open Label, Adaptive Phase-3 Trial to Evaluate Safety and Efficacy of EndoTAG-1+GEM vs GEM Alone in Patients With Measurable Locally Advanced/Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment

Outcome
Primary endpoint: no statistically significant difference (p = 0.6647, as posted; no threshold posted, 0.05 used)
Phase
Phase 3
Status
Completed
Study type
Interventional
Start
16 October 2018
Ended
8 October 2021
Enrollment
218 participants
Sites
68
Primary outcomes
Overall Survival
Sponsor type
Industry
Results posted
24 March 2023
Last update
6 May 2023

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Results

Primary endpoint
Primary endpoint: no statistically significant difference (p = 0.6647, as posted; no threshold posted, 0.05 used)As posted on ClinicalTrials.gov ↗, registry record of 6 May 2023
OS
Overall SurvivalEndoTAG-1 and Gemcitabine: 226 (183.0 to 278.0), n = 108Gemcitabine Monotherapy: 209 (158.0 to 248.0), n = 110EndoTAG-1 and Gemcitabine vs Gemcitabine Monotherapy: p = 0.6647; Log Rank (not statistically significant against 0.05 (no threshold posted); outcome 1, analysis 1)Values: median days, 95% Confidence IntervalTime frame: From randomization to death from any cause or last day known to be alive, up to approximately 33.5 months (assessed continuously during treatment)
Participants
EndoTAG-1 and Gemcitabine: 108 started, 2 completedGemcitabine Monotherapy: 110 started, 6 completed
Serious adverse events
EndoTAG-1 and Gemcitabine: 52 of 102Gemcitabine Monotherapy: 48 of 102Participants with at least one serious adverse event, of those at risk, as posted
5 secondary outcomes
PFS · Progression Free Survival (PFS)
EndoTAG-1 and Gemcitabine 113 (79.0 to 168.0), n=108; Gemcitabine Monotherapy 110 (60.0 to 115.0), n=110 [median days, 95% Confidence Interval] EndoTAG-1 and Gemcitabine vs Gemcitabine Monotherapy: p = 0.4345; Log Rank
ORR · Percentage of Subjects With Objective Response
EndoTAG-1 and Gemcitabine 11/96; Gemcitabine Monotherapy 6/88 [Participants] EndoTAG-1 and Gemcitabine vs Gemcitabine Monotherapy: p = 0.2632; Regression, Logistic
Duration of Response
EndoTAG-1 and Gemcitabine 5.8 (2.62), n=11; Gemcitabine Monotherapy 9.1 (6.97), n=6 [mean Months, Standard Deviation]
DCR · Percentage of Subjects With Disease Control According to RECIST v.1.1
EndoTAG-1 and Gemcitabine 57/96; Gemcitabine Monotherapy 43/88 [Participants] EndoTAG-1 and Gemcitabine vs Gemcitabine Monotherapy: p = 0.1002; Regression, Logistic
Serum Carcinoma Antigen 19-9 (CA 19-9) Response Rate
EndoTAG-1 and Gemcitabine 2/108; Gemcitabine Monotherapy 2/110 [Participants] EndoTAG-1 and Gemcitabine vs Gemcitabine Monotherapy: p = 0.9882; Regression, Logistic

Every value is copied from the trial’s results record at ClinicalTrials.gov. “Statistically significant” describes the posted test only: it does not say which group did better, and nothing here is read from a paper.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

The aim of this adaptive Phase 3 trial is to show a statistically significant superiority of EndoTAG-1 in combination with gemcitabine compared to gemcitabine monotherapy in patients with locally advanced/metastatic pancreatic cancer after FOLFIRINOX failure.

Detailed description public domain (ClinicalTrials.gov)

The objective of the study was to assess the safety and efficacy of a combination therapy of EndoTAG-1 plus gemcitabine vs. gemcitabine monotherapy in patients with locally advanced and/or metastatic adenocarcinoma of the pancreas eligible for second-line therapy after failing first line therapy with FOLFIRINOX

Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)

Overall Survival [From randomization to death from any cause or last day known to be alive, up to approximately 33.5 months (assessed continuously during treatment)]. Median, days (95% Confidence Interval). EndoTAG-1 and Gemcitabine (n=108): 226 (183.0 to 278.0); Gemcitabine Monotherapy (n=110): 209 (158.0 to 248.0). Analysis, EndoTAG-1 and Gemcitabine vs Gemcitabine Monotherapy: p=0.6647; Log Rank; superiority.

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Progression Free Survival (PFS) [From randomization to either first observation of progressive disease or occurrence of death, up to approximately 33.5 months (assessed continuously during treatment)]. Median, days (95% Confidence Interval). EndoTAG-1 and Gemcitabine (n=108): 113 (79.0 to 168.0); Gemcitabine Monotherapy (n=110): 110 (60.0 to 115.0). Analysis, EndoTAG-1 and Gemcitabine vs Gemcitabine Monotherapy: p=0.4345; Log Rank; superiority.

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Percentage of Subjects With Objective Response [Up to approximately 33.5 months (assessed continuously during treatment)]. Count Of Participants, Participants. EndoTAG-1 and Gemcitabine (n=96): 11; Gemcitabine Monotherapy (n=88): 6. Analysis, EndoTAG-1 and Gemcitabine vs Gemcitabine Monotherapy: p=0.2632; Regression, Logistic; superiority.

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Duration of Response [From the first documentation of objective tumor response (date of the first CR or PR) to objective tumor progression or death due to any cause.]. Mean, Months (Standard Deviation). EndoTAG-1 and Gemcitabine (n=11): 5.8 (2.62); Gemcitabine Monotherapy (n=6): 9.1 (6.97).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Percentage of Subjects With Disease Control According to RECIST v.1.1 [Up to approximately 33.5 months (assessed continuously during treatment)]. Count Of Participants, Participants. EndoTAG-1 and Gemcitabine (n=96): 57; Gemcitabine Monotherapy (n=88): 43. Analysis, EndoTAG-1 and Gemcitabine vs Gemcitabine Monotherapy: p=0.1002; Regression, Logistic; superiority.

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Serum Carcinoma Antigen 19-9 (CA 19-9) Response Rate [Up to approximately 33.5 months (assessed at baseline, end of cycle 1 or the full treatment course)]. Count Of Participants, Participants. EndoTAG-1 and Gemcitabine (n=108): 2; Gemcitabine Monotherapy (n=110): 2. Analysis, EndoTAG-1 and Gemcitabine vs Gemcitabine Monotherapy: p=0.9882; Regression, Logistic; superiority.